Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET

Sharon Ashworth, Eugenii A. Rabiner, Roger N. Gunn, Christophe Plisson, Alan A. Wilson, Robert A. Comley, Robert Y. K. Lai, Antony D. Gee, Marc Laruelle, Vincent Joseph Cunningham

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The histamine H-3 receptor is implicated in the pathophysiology of several central nervous system disorders. N-methyl-6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-nicotamide (GSK189254) is a highly potent, selective, and brain-penetrant H-3 receptor antagonist. Previous studies in the pig using PET have shown that C-11-GSK189254 uptake in H-3-rich regions of the brain can be blocked by the selective H-3 antagonist ciproxifan. The purpose of the present study was to evaluate C-11-GSK189254 as a PET radioligand for human studies and to determine the dose-receptor occupancy relationship of GSK189254 in the human brain. Methods: Dynamic PET scans were obtained in healthy subjects over 90 min after intravenous administration of approximately 370 MBq of C-11-GSK189254. Blood samples were taken throughout the scans to derive the arterial plasma parent input function. Each subject was scanned twice, either with tracer alone (test-retest) or before and after a single oral dose of GSK189254 (10-100 mu g). Data were analyzed by compartmental analysis, and regional receptor-occupancy estimates were obtained by graphical analysis of changes in the total volumes of distribution (V-T) of the radioligand. Results: C-11-GSK189254 readily entered the brain; its regional brain distribution reflected the known distribution of H-3 receptors, with high binding in the caudate and putamen, intermediate binding in cortical regions, and low binding in the cerebellum. GSK189254 displayed a high receptor affinity, and a marked reduction in V-T was apparent at all the doses tested. The oral dose equaling 50% occupancy of the available receptor sites (ED50) was estimated as 4.33 mu g. Additional data on plasma pharmacokinetics after oral dosing and the plasma free fraction gave a corresponding estimate of the free concentration of GSK189254 required to occupy 50% of the available receptor sites (EC50) (0.011 nM). The test-retest data showed reductions in regional V-T on the second scan in all subjects. A nonlinear compartmental analysis of this effect demonstrated that this reduction was consistent with carryover of a tracer mass dose effect with an estimated in vivo apparent dissociation constant of 0.010 nM, close to the independent estimate of the plasma EC50. Conclusion: C-11-GSK189254 can be used to quantify H-3 receptor availability in humans in vivo using PET but requires high specific activity; the possibility of tracer mass dose effects should be carefully analyzed.

Original languageEnglish
Pages (from-to)1021-1029
Number of pages9
JournalJournal of Nuclear Medicine
Volume51
Issue number7
Early online date16 Jun 2010
DOIs
Publication statusPublished - Jul 2010

Keywords

  • neurology
  • PET
  • radiopharmaceuticals
  • brain
  • GSK189254
  • H-3 receptor
  • human
  • histamine-receptors
  • brain histamine
  • H-3-receptor
  • performance
  • antagonist
  • striatum
  • release
  • ligands
  • agonist
  • disease

Cite this

Ashworth, S., Rabiner, E. A., Gunn, R. N., Plisson, C., Wilson, A. A., Comley, R. A., ... Cunningham, V. J. (2010). Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET. Journal of Nuclear Medicine, 51(7), 1021-1029. https://doi.org/10.2967/jnumed.109.071753

Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET. / Ashworth, Sharon; Rabiner, Eugenii A.; Gunn, Roger N.; Plisson, Christophe; Wilson, Alan A.; Comley, Robert A.; Lai, Robert Y. K.; Gee, Antony D.; Laruelle, Marc; Cunningham, Vincent Joseph.

In: Journal of Nuclear Medicine, Vol. 51, No. 7, 07.2010, p. 1021-1029.

Research output: Contribution to journalArticle

Ashworth, S, Rabiner, EA, Gunn, RN, Plisson, C, Wilson, AA, Comley, RA, Lai, RYK, Gee, AD, Laruelle, M & Cunningham, VJ 2010, 'Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET', Journal of Nuclear Medicine, vol. 51, no. 7, pp. 1021-1029. https://doi.org/10.2967/jnumed.109.071753
Ashworth, Sharon ; Rabiner, Eugenii A. ; Gunn, Roger N. ; Plisson, Christophe ; Wilson, Alan A. ; Comley, Robert A. ; Lai, Robert Y. K. ; Gee, Antony D. ; Laruelle, Marc ; Cunningham, Vincent Joseph. / Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET. In: Journal of Nuclear Medicine. 2010 ; Vol. 51, No. 7. pp. 1021-1029.
@article{68a0559eca1549aeadd109700722135a,
title = "Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET",
abstract = "The histamine H-3 receptor is implicated in the pathophysiology of several central nervous system disorders. N-methyl-6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-nicotamide (GSK189254) is a highly potent, selective, and brain-penetrant H-3 receptor antagonist. Previous studies in the pig using PET have shown that C-11-GSK189254 uptake in H-3-rich regions of the brain can be blocked by the selective H-3 antagonist ciproxifan. The purpose of the present study was to evaluate C-11-GSK189254 as a PET radioligand for human studies and to determine the dose-receptor occupancy relationship of GSK189254 in the human brain. Methods: Dynamic PET scans were obtained in healthy subjects over 90 min after intravenous administration of approximately 370 MBq of C-11-GSK189254. Blood samples were taken throughout the scans to derive the arterial plasma parent input function. Each subject was scanned twice, either with tracer alone (test-retest) or before and after a single oral dose of GSK189254 (10-100 mu g). Data were analyzed by compartmental analysis, and regional receptor-occupancy estimates were obtained by graphical analysis of changes in the total volumes of distribution (V-T) of the radioligand. Results: C-11-GSK189254 readily entered the brain; its regional brain distribution reflected the known distribution of H-3 receptors, with high binding in the caudate and putamen, intermediate binding in cortical regions, and low binding in the cerebellum. GSK189254 displayed a high receptor affinity, and a marked reduction in V-T was apparent at all the doses tested. The oral dose equaling 50{\%} occupancy of the available receptor sites (ED50) was estimated as 4.33 mu g. Additional data on plasma pharmacokinetics after oral dosing and the plasma free fraction gave a corresponding estimate of the free concentration of GSK189254 required to occupy 50{\%} of the available receptor sites (EC50) (0.011 nM). The test-retest data showed reductions in regional V-T on the second scan in all subjects. A nonlinear compartmental analysis of this effect demonstrated that this reduction was consistent with carryover of a tracer mass dose effect with an estimated in vivo apparent dissociation constant of 0.010 nM, close to the independent estimate of the plasma EC50. Conclusion: C-11-GSK189254 can be used to quantify H-3 receptor availability in humans in vivo using PET but requires high specific activity; the possibility of tracer mass dose effects should be carefully analyzed.",
keywords = "neurology, PET, radiopharmaceuticals, brain, GSK189254, H-3 receptor, human, histamine-receptors, brain histamine, H-3-receptor, performance, antagonist, striatum, release, ligands, agonist, disease",
author = "Sharon Ashworth and Rabiner, {Eugenii A.} and Gunn, {Roger N.} and Christophe Plisson and Wilson, {Alan A.} and Comley, {Robert A.} and Lai, {Robert Y. K.} and Gee, {Antony D.} and Marc Laruelle and Cunningham, {Vincent Joseph}",
year = "2010",
month = "7",
doi = "10.2967/jnumed.109.071753",
language = "English",
volume = "51",
pages = "1021--1029",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET

AU - Ashworth, Sharon

AU - Rabiner, Eugenii A.

AU - Gunn, Roger N.

AU - Plisson, Christophe

AU - Wilson, Alan A.

AU - Comley, Robert A.

AU - Lai, Robert Y. K.

AU - Gee, Antony D.

AU - Laruelle, Marc

AU - Cunningham, Vincent Joseph

PY - 2010/7

Y1 - 2010/7

N2 - The histamine H-3 receptor is implicated in the pathophysiology of several central nervous system disorders. N-methyl-6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-nicotamide (GSK189254) is a highly potent, selective, and brain-penetrant H-3 receptor antagonist. Previous studies in the pig using PET have shown that C-11-GSK189254 uptake in H-3-rich regions of the brain can be blocked by the selective H-3 antagonist ciproxifan. The purpose of the present study was to evaluate C-11-GSK189254 as a PET radioligand for human studies and to determine the dose-receptor occupancy relationship of GSK189254 in the human brain. Methods: Dynamic PET scans were obtained in healthy subjects over 90 min after intravenous administration of approximately 370 MBq of C-11-GSK189254. Blood samples were taken throughout the scans to derive the arterial plasma parent input function. Each subject was scanned twice, either with tracer alone (test-retest) or before and after a single oral dose of GSK189254 (10-100 mu g). Data were analyzed by compartmental analysis, and regional receptor-occupancy estimates were obtained by graphical analysis of changes in the total volumes of distribution (V-T) of the radioligand. Results: C-11-GSK189254 readily entered the brain; its regional brain distribution reflected the known distribution of H-3 receptors, with high binding in the caudate and putamen, intermediate binding in cortical regions, and low binding in the cerebellum. GSK189254 displayed a high receptor affinity, and a marked reduction in V-T was apparent at all the doses tested. The oral dose equaling 50% occupancy of the available receptor sites (ED50) was estimated as 4.33 mu g. Additional data on plasma pharmacokinetics after oral dosing and the plasma free fraction gave a corresponding estimate of the free concentration of GSK189254 required to occupy 50% of the available receptor sites (EC50) (0.011 nM). The test-retest data showed reductions in regional V-T on the second scan in all subjects. A nonlinear compartmental analysis of this effect demonstrated that this reduction was consistent with carryover of a tracer mass dose effect with an estimated in vivo apparent dissociation constant of 0.010 nM, close to the independent estimate of the plasma EC50. Conclusion: C-11-GSK189254 can be used to quantify H-3 receptor availability in humans in vivo using PET but requires high specific activity; the possibility of tracer mass dose effects should be carefully analyzed.

AB - The histamine H-3 receptor is implicated in the pathophysiology of several central nervous system disorders. N-methyl-6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-nicotamide (GSK189254) is a highly potent, selective, and brain-penetrant H-3 receptor antagonist. Previous studies in the pig using PET have shown that C-11-GSK189254 uptake in H-3-rich regions of the brain can be blocked by the selective H-3 antagonist ciproxifan. The purpose of the present study was to evaluate C-11-GSK189254 as a PET radioligand for human studies and to determine the dose-receptor occupancy relationship of GSK189254 in the human brain. Methods: Dynamic PET scans were obtained in healthy subjects over 90 min after intravenous administration of approximately 370 MBq of C-11-GSK189254. Blood samples were taken throughout the scans to derive the arterial plasma parent input function. Each subject was scanned twice, either with tracer alone (test-retest) or before and after a single oral dose of GSK189254 (10-100 mu g). Data were analyzed by compartmental analysis, and regional receptor-occupancy estimates were obtained by graphical analysis of changes in the total volumes of distribution (V-T) of the radioligand. Results: C-11-GSK189254 readily entered the brain; its regional brain distribution reflected the known distribution of H-3 receptors, with high binding in the caudate and putamen, intermediate binding in cortical regions, and low binding in the cerebellum. GSK189254 displayed a high receptor affinity, and a marked reduction in V-T was apparent at all the doses tested. The oral dose equaling 50% occupancy of the available receptor sites (ED50) was estimated as 4.33 mu g. Additional data on plasma pharmacokinetics after oral dosing and the plasma free fraction gave a corresponding estimate of the free concentration of GSK189254 required to occupy 50% of the available receptor sites (EC50) (0.011 nM). The test-retest data showed reductions in regional V-T on the second scan in all subjects. A nonlinear compartmental analysis of this effect demonstrated that this reduction was consistent with carryover of a tracer mass dose effect with an estimated in vivo apparent dissociation constant of 0.010 nM, close to the independent estimate of the plasma EC50. Conclusion: C-11-GSK189254 can be used to quantify H-3 receptor availability in humans in vivo using PET but requires high specific activity; the possibility of tracer mass dose effects should be carefully analyzed.

KW - neurology

KW - PET

KW - radiopharmaceuticals

KW - brain

KW - GSK189254

KW - H-3 receptor

KW - human

KW - histamine-receptors

KW - brain histamine

KW - H-3-receptor

KW - performance

KW - antagonist

KW - striatum

KW - release

KW - ligands

KW - agonist

KW - disease

U2 - 10.2967/jnumed.109.071753

DO - 10.2967/jnumed.109.071753

M3 - Article

VL - 51

SP - 1021

EP - 1029

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -